Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells

Cytotherapy

Volumn 18, Issue 11, 2016, Pages 1393-1409

  Geyer, Mark B ^a   Brentjens, Renier J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

acute lymphoblastic leukemia; adoptive cellular therapy; CAR T cells; chimeric antigen receptors; cytokine release syndrome

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE CELLULAR THERAPY; ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CELL EXPANSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE SYNDROME; DISEASE SEVERITY; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE STRUCTURE; MULTIPLE MYELOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY; NEOPLASMS; PROCEDURES;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84992655487     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.07.003     Document Type: Review

References (73)

1. [1] Park, J.H., Brentjens, R.J., Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 9 (2010), 277–288.
2. [2] Till, B.G., Jensen, M.C., Wang, J., Qian, X., Gopal, A.K., Maloney, D.G., et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119 (2012), 3940–3950, 10.1182/blood-2011-10-387969.
3. [3] Davenport, A.J., Jenkins, M.R., Cross, R.S., Yong, C.S., Prince, H.M., Ritchie, D.S., et al. CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells. Cancer Immunol Res 3 (2015), 483–494, 10.1158/2326-6066.CIR-15-0048.
4. [4] Kantarjian, H.M., Thomas, D., Ravandi, F., Faderl, S., Jabbour, E., Garcia-Manero, G., et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 116 (2010), 5568–5574, 10.1002/cncr.25354.
5. [5] Gokbuget, N., Stanze, D., Beck, J., Diedrich, H., Horst, H.A., Huttmann, A., et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120 (2012), 2032–2041, 10.1182/blood-2011-12-399287.
6. [6] Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med, 5, 2013, 10.1126/scitranslmed.3005930 177ra138.
7. [7] Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 6, 2014, 10.1126/scitranslmed.3008226 224ra225.
8. [8] Park, J.H., Riviere, I., Wang, X., Purdon, T., Sadelain, M., Brentjens, R.J., Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL. J Clin Oncol, 34(Suppl.), 2016 abstr 7003.
9. [9] Park, J.H., Riviere, I., Wang, X., Bernal, Y., Purdon, T., Halton, E., et al. Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL. Blood, 126, 2015, 682.
10. [10] Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., Sadelain, M., Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18 (2010), 666–668, 10.1038/mt.2010.31.
11. [11] Turtle, C.J., Hanafi, L.A., Berger, C., Gooley, T.A., Cherian, S., Hudecek, M., et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 126 (2016), 2123–2138, 10.1172/JCI85309.
12. [12] Turtle, C.J., Hanafi, L.-A., Berger, C., Sommermeyer, D., Pender, B., Robinson, E.M., et al. Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. Blood, 126, 2015, 3773.
13. [13] Frey, N.V., Shaw, P.A., Hexner, E.O., Gill, S., Marcucci, K., Luger, S.M., et al. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). J Clin Oncol, 34(Suppl.), 2016 abstr 7002.
14. [14] Nguyen, K., Devidas, M., Cheng, S.C., La, M., Raetz, E.A., Carroll, W.L., et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 22 (2008), 2142–2150, 10.1038/Leu.2008.251.
15. [15] Gaynon, P.S., Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 131 (2005), 579–587, 10.1111/j.1365-2141.2005.05773.x BJH5773 [pii].
16. [16] Reismuller, B., Peters, C., Dworzak, M.N., Potschger, U., Urban, C., Meister, B., et al. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group. J Pediatr Hematol Oncol 35 (2013), e200–4, 10.1097/MPH.0b013e318290c3d6.
17. [17] Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368 (2013), 1509–1518, 10.1056/NEJMoa1215134.
18. [18] Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371 (2014), 1507–1517, 10.1056/NEJMoa1407222.
19. [19] Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385 (2015), 517–528, 10.1016/S0140-6736(14)61403-3.
20. [20] Curran, K.J., Riviere, I., Silverman, L.B., Kobos, R., Shukla, N., Steinherz, P.G., et al. Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL. Blood, 126, 2015, 2533.
21. [21] Frey, N.V., Levine, B.L., Lacey, S.F., Grupp, S.A., Maude, S.L., Schuster, S.J., et al. Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells. Blood, 124, 2014, 2296.
22. [22] Tam, C.S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.A., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112 (2008), 975–980, 10.1182/blood-2008-02-140582.
23. [23] Kay, N.E., Geyer, S.M., Call, T.G., Shanafelt, T.D., Zent, C.S., Jelinek, D.F., et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109 (2007), 405–411, 10.1182/blood-2006-07-033274.
24. [24] Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369 (2013), 32–42, 10.1056/NEJMoa1215637.
25. [25] Byrd, J.C., Furman, R.R., Coutre, S.E., Burger, J.A., Blum, K.A., Coleman, M., et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125 (2015), 2497–2506, 10.1182/blood-2014-10-606038.
26. [26] Brentjens, R.J., Riviere, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118 (2011), 4817–4828, 10.1182/blood-2011-04-348540.
27. [27] Geyer, M.B., Park, J.H., Riviere, I., Wang, X., Purdon, T., Sadelain, M., et al. Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. J Clin Oncol, 34(Suppl.), 2016 abstr 7526.
28. [28] Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365 (2011), 725–733, 10.1056/NEJMoa1103849.
29. [29] Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med, 3, 2011, 10.1126/scitranslmed.3002842 95ra73.
30. [30] Porter, D.L., Hwang, W.T., Frey, N.V., Lacey, S.F., Shaw, P.A., Loren, A.W., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med, 7, 2015, 10.1126/scitranslmed.aac5415 303ra139.
31. [31] Porter, D.L., Frey, N.V., Melenhorst, J.J., Hwang, W.T., Lacey, S.F., Shaw, P.A., et al. Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL. J Clin Oncol, 34(Suppl.), 2016 abstr 3009.
32. [32] Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116 (2010), 4099–4102, 10.1182/blood-2010-04-281931.
33. [33] Kochenderfer, J.N., Feldman, S.A., Zhao, Y., Xu, H., Black, M.A., Morgan, R.A., et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 32 (2009), 689–702, 10.1097/CJI.0b013e3181ac6138.
34. [34] Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 (2012), 2709–2720, 10.1182/blood-2011-10-384388.
35. [35] Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P., Carpenter, R.O., Stetler-Stevenson, M., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33 (2015), 540–549, 10.1200/JCO.2014.56.2025.
36. [36] Schuster, S.J., Svoboda, J., Nasta, S.D., Porter, D.L., Chong, E.A., Landsburg, D.J., et al. Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas. Blood, 126, 2015, 183.
37. [37] Turtle, C.J., Berger, C., Sommermeyer, D., Hanafi, L.A., Pender, B., Robinson, E.M., et al. Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. Blood, 126, 2015, 184.
38. [38] Sauter, C.S., Riviere, I., Bernal, Y., Wang, X., Purdon, T., Yoo, S., et al. Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL). J Clin Oncol, 33(Suppl.), 2015 abstr 8515.
39. [39] Garfall, A.L., Maus, M.V., Hwang, W.T., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med 373 (2015), 1040–1047, 10.1056/NEJMoa1504542.
40. [40] Danhof, S., Gogishvili, T., Koch, S., Schreder, M., Knop, S., Einsele, H., et al. CAR-Engineered T Cells Specific for the Elotuzumab Target SLAMF7 Eliminate Primary Myeloma Cells and Confer Selective Fratricide of SLAMF7+ Normal Lymphocyte Subsets. Blood, 126, 2015, 115.
41. [41] Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373 (2015), 621–631, 10.1056/NEJMoa1505654.
42. [42] Ali, S.A., Shi, V., Wang, M.L., Stroncek, D., Maric, I., Brudno, J.N., et al. Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor. ASH Annual Meeting: Late-Breaking Abstracts, 2015 p. LBA-1.
43. [43] Ryan, M.C., Hering, M., Peckham, D., McDonagh, C.F., Brown, L., Kim, K.M., et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther 6 (2007), 3009–3018, 10.1158/1535-7163.MCT-07-0464.
44. [44] Ramadoss, N.S., Schulman, A.D., Choi, S.H., Rodgers, D.T., Kazane, S.A., Kim, C.H., et al. An anti-B cell maturation antigen bispecific antibody for multiple myeloma. J Am Chem Soc 137 (2015), 5288–5291, 10.1021/jacs.5b01876.
45. [45] Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol 33 (2015), 1688–1696, 10.1200/JCO.2014.58.0225.
46. [46] Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., Rosenberg, S.A., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18 (2010), 843–851, 10.1038/mt.2010.24.
47. [47] Weiner, L.M., Clark, J.I., Davey, M., Li, W.S., Garcia de Palazzo, I., Ring, D.B., et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 55 (1995), 4586–4593.
48. [48] Koneru, M., O'Cearbhaill, R., Pendharkar, S., Spriggs, D.R., Brentjens, R.J., A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med, 13, 2015, 102, 10.1186/s12967-015-0460-x.
49. [49] Hassan, R., Bullock, S., Premkumar, A., Kreitman, R.J., Kindler, H., Willingham, M.C., et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13 (2007), 5144–5149, 10.1158/1078-0432.CCR-07-0869.
50. [50] Feng, Y., Xiao, X., Zhu, Z., Streaker, E., Ho, M., Pastan, I., et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther 8 (2009), 1113–1118, 10.1158/1535-7163.MCT-08-0945.
51. [51] Cruz, C.R., Micklethwaite, K.P., Savoldo, B., Ramos, C.A., Lam, S., Ku, S., et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122 (2013), 2965–2973, 10.1182/blood-2013-06-506741.
52. [52] Brudno, J.N., Somerville, R.P., Shi, V., Rose, J.J., Halverson, D.C., Fowler, D.H., et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol 34 (2016), 1112–1121, 10.1200/JCO.2015.64.5929.
53. [53] Grupp, S.A., Maude, S.L., Shaw, P.A., Aplenc, R., Barrett, D., Callahan, C., et al. Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019). Blood, 126, 2015, 681.
54. [54] Sommermeyer, D., Hudecek, M., Kosasih, P.L., Gogishvili, T., Maloney, D.G., Turtle, C.J., et al. Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo. Leukemia 30 (2016), 492–500, 10.1038/leu.2015.247.
55. [55] Minagawa, K., Zhou, X., Mineishi, S., Di Stasi, A., Seatbelts in CAR therapy: How Safe Are CARS?. Pharmaceuticals 8 (2015), 230–249, 10.3390/ph8020230.
56. [56] Topp, M.S., Gokbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32 (2014), 4134–4140, 10.1200/JCO.2014.56.3247.
57. [57] Park, K.H., Riviere, I., Wang, X., Bernal, Y., Purdon, T., Halton, E., et al. Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. J Clin Oncol, 33(Suppl.), 2015 abstr 7010.
58. [58] Sotillo, E., Barrett, D.M., Black, K.L., Bagashev, A., Oldridge, D., Wu, G., et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov 5 (2015), 1282–1295, 10.1158/2159-8290.CD-15-1020.
59. [59] Jackson, H.J., Brentjens, R.J., Overcoming Antigen Escape with CAR T-cell Therapy. Cancer Discov 5 (2015), 1238–1240, 10.1158/2159-8290.CD-15-1275.
60. [60] Reiners, K.S., Topolar, D., Henke, A., Simhadri, V.R., Kessler, J., Sauer, M., et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 121 (2013), 3658–3665, 10.1182/blood-2013-01-476606.
61. [61] Ramsay, A.G., Clear, A.J., Fatah, R., Gribben, J.G., Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 120 (2012), 1412–1421, 10.1182/blood-2012-02-411678.
62. [62] Gorgun, G., Holderried, T.A., Zahrieh, D., Neuberg, D., Gribben, J.G., Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 115 (2005), 1797–1805, 10.1172/JCI24176.
63. [63] McClanahan, F., Hanna, B., Miller, S., Clear, A.J., Lichter, P., Gribben, J.G., et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood 126 (2015), 203–211, 10.1182/blood-2015-01-622936.
64. [64] Riches, J.C., Davies, J.K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121 (2013), 1612–1621, 10.1182/blood-2012-09-457531.
65. [65] Paggetti, J., Haderk, F., Seiffert, M., Janji, B., Distler, U., Ammerlaan, W., et al. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood, 2015, 10.1182/blood-2014-12-618025.
66. [66] Curran, K.J., Seinstra, B.A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D.G., et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther 23 (2015), 769–778, 10.1038/mt.2015.4.
67. [67] Pegram, H.J., Lee, J.C., Hayman, E.G., Imperato, G.H., Tedder, T.F., Sadelain, M., et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119 (2012), 4133–4141, 10.1182/blood-2011-12-400044.
68. [68] Pegram, H.J., Purdon, T.J., van Leeuwen, D.G., Curran, K.J., Giralt, S.A., Barker, J.N., et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia 29 (2015), 415–422, 10.1038/leu.2014.215.
69. [69] Stephan, M.T., Ponomarev, V., Brentjens, R.J., Chang, A.H., Dobrenkov, K.V., Heller, G., et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 13 (2007), 1440–1449, 10.1038/nm1676.
70. [70] Koneru, M., Purdon, T.J., Spriggs, D., Koneru, S., Brentjens, R.J., IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors. Oncoimmunology, 4, 2015, e994446, 10.4161/2162402X.2014.994446.
71. [71] John, L.B., Kershaw, M.H., Darcy, P.K., Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology, 2, 2013, e26286, 10.4161/onci.26286.
72. [72] Fraietta, J.A., Beckwith, K.A., Patel, P.R., Ruella, M., Zheng, Z., Barrett, D.M., et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, 10.1182/blood-2015-11-679134.
73. [73] Fedorov, V.D., Themeli, M., Sadelain, M., PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med, 5, 2013, 10.1126/scitranslmed.3006597 215ra172.